Etoposide Soft Capsules

This product is a cell cycle-specific anti-tumor drug that acts on DNA topoisomerase II to form a stable reversible complex of drug-enzyme-DNA, which hinders DNA repair. Experiments have found that this complex can be reversed with the elimination of the drug, allowing the damaged DNA to be repaired and reducing cytotoxicity. Therefore, extending the drug administration time may improve the anti-tumor activity.

The main ingredient of this product is etoposide.

This product is a soft capsule, the contents of which are colorless or light yellow clear viscous liquid.

It is mainly used to treat small cell lung cancer, malignant lymphoma, malignant germ cell tumor, leukemia, and has certain therapeutic effects on neuroblastoma, rhabdomyosarcoma, ovarian cancer, non-small cell lung cancer, gastric cancer and esophageal cancer.

Single use: 60-100 mg/m2 per day for 10 consecutive days, repeated every 3-4 weeks. Combined chemotherapy: 50 mg/m2/day for 3 or 5 consecutive days.

The main toxicity is hematological and gastrointestinal toxicity. Compared with intravenous preparations, the incidence of vomiting is lower. Severe allergic reactions may occur in rare cases and should be taken seriously.

People who are allergic to this product, pregnant women and breastfeeding women are forbidden to use it.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not allowed. Precautions for the elderly: Not yet clear.

Not yet clear.

Keep away from light, tightly closed, in a cool place.

50mg

24 months